Introduction
From 2012 to 2013, five independent meta-analyses (MAs) of the value of intrapartum fetal surveillance with cardiotocography (CTG) plus ST interval analysis (CTG+ST) of the electrocardiogram compared with CTG alone were published (1) (2) (3) (4) (5) . In the same time frame, international clinical experience with the CTG+ST analysis method increased, as noted in numerous observational studies (6) (7) (8) (9) (10) (11) . With the current attention focused on the CTG+ST fetal surveillance method, we believe that a thorough review of the quality of the original five randomized controlled trials (RCTs) (12) (13) (14) (15) (16) was warranted, as well as a critical review of the quality of the five MAs that have followed (1) (2) (3) (4) (5) . This article addresses the quality of the RCTs, while a companion piece will focus on the MAs.
Five randomized controlled trials
Our review addressed the following issues in the RCTs: (i) power calculations; (ii) pre-study training, inclusion criteria, randomization and recruitment pace; (iii) intrapartum management protocols; (iv) intrapartum interventions; (v) cord blood and early neonatal metabolic acidosis; (vi) neonatal outcomes. For supplementary statistical calculations, we used the MEDCALC â version 5.00.017 computer software (MedCalc Software, Mariakerke, Belgium). Two-sided statistics were performed with a p-value <0.05 considered significant. The first RCT on CTG+ST analysis vs. CTG alone, the Plymouth trial, was published in 1993 (12) , followed by the Swedish trial in 2001 (13) , the Finnish trial in 2006 (14) , the French trial in 2007 (15) , and the Dutch trial in 2010 (16) . After receiving criticism about quality control, revised data from the Swedish and Dutch RCTs were published in 2011 (17) (18) (19) . Metabolic acidosis data from the Finnish RCT have been revised (see below), but data from the Plymouth and French RCTs have not been revised.
Power calculations of outcome variables
Neonatal metabolic acidosis was the primary outcome variable in the Plymouth, Swedish and Dutch RCTs but not in the Finnish and French RCTs. Table 1 shows that neither the Finnish nor French RCTs were adequately powered to address this outcome. Due to a 46.5 and 73% lower than expected incidence of metabolic acidosis in the Plymouth and the Dutch RCTs, respectively, these trials were also found to be underpowered for this outcome (Table 1) . Therefore, the majority of the RCTs failed to attain their recruitment goals and/or were underpowered for their primary outcome. Estimation of the incidences of the primary endpoints was accurate in the control group (i.e. in the CTG-alone group) only in the Swedish RCT (metabolic acidosis) and in the Plymouth RCT (operative delivery for fetal distress, ODFD).
Pre-trial training, inclusion criteria, randomization and recruitment pace While all RCTs offered some form of pre-trial training (Table 2) , the Plymouth RCT included a 100-case test period before enrollment. The Swedish RCT required a 2-month practice period before enrollment started and there was re-training during the trial. The Dutch RCT required certification and a 2-month practice period before enrollment started. It therefore seems that these three RCTs dealt more carefully with the potential problem of staff proficiency in applying the ST analysis methodology to clinical care, thereby increasing the likelihood of its proper use.
An interim analysis or safety committee watch was performed in all but the Finnish and French RCTs ( Table 2 ). The inclusion criteria differed among the RCTs. The most important difference was noted in the French RCT, as the investigators recruited only cases considered to have suspicious or pathological CTGs (86% of enrollees) or thick meconium-stained amniotic fluid (7%), or both (7%) at the start-up of monitoring. Cases with a normal CTG and no decelerations were excluded. However, the inclusion of patients with a pathological CTG at start-up of ST analysis violated the CTG+ST analysis clinical guidelines (20) . To enable establishment of a fetal electrocardiogram T/QRS ratio baseline, ST monitoring should be initiated while the fetus is still well oxygenated and the CTG is not pathological. The French RCT data included in the MA by Schuit et al. (5) indicate that in several cases deterioration of the fetal condition might have already occurred before enrollment. The basis for this requirement is that alerts for changes in the ST interval, signaling fetal hypoxia and impending metabolic acidosis, may not occur if the fetal condition has already deteriorated and myocardial reserve is exhausted. Consequently, the prerequisites for use of the CTG+ST analysis method were not fulfilled in many cases in the French RCT.
Key Message
Among the randomized controlled trials, the Plymouth, Swedish and Dutch trials have the most similar design and therefore should be the main source of information regarding the effectiveness of CTG+ST analysis for fetal surveillance in labor. In the Plymouth, Swedish and Dutch RCTs, cases at increased risk of fetal hypoxia in labor were recruited ( Table 2) . Inclusion of cases with a nonreassuring fetal heart rate was also allowed in these RCTs, but the majority of cases recruited in the French RCT were at considerably higher risk. This is illustrated by the crude French RCT data presented in the MA by Schuit et al. (5), where a composite adverse outcome was two to four times more common in the French RCT than in the other RCTs. In the Finnish RCT recruitment was made consecutively after amniotomy. It is unclear whether amniotomy was a routine procedure for active management of labor or performed for specific indications.
The monitoring techniques in the CTG arm of the RCTs varied (Table 2 ). Only the Swedish RCT used STAN â S21 monitors (Neoventa Medical AB, G€ oteborg, Sweden) for both study groups, while the other RCTs used different monitoring systems, allowed external CTG recording or did not specify the methodology used in the control groups. In general, external fetal heart rate monitoring provides inferior CTG signal quality when compared with internal signals (21) . This might have introduced bias in the CTG-only group in the RCTs that allowed this modality. Robust methods for allocation of women were used in all five RCTs but standardized intention-to-treat (ITT) analyses, including patients later excluded for various reasons, were not generally available (Table 2) . A revised report of the Swedish RCT that included all randomized cases (17) was the only effort to address this issue. However, the Dutch RCT excluded only 14 cases (0.25%) from the ITT.
Leip€ al€ a et al. (22) requested an explanation of why the Swedish trial was revisited. The original Swedish RCT (13) was reported as a per-protocol analysis and by modified ITT analysis, i.e. including only the 4966 eligible cases. After criticism for not including all randomized cases and for misclassification of cases, a so-called standardized ITT on the primary outcome parameter metabolic acidosis was performed (17) . In the standardized ITT analysis (n = 5049), 83 allocated cases that did not fulfill the inclusion criteria were added. These were cases of delivery before 36 weeks of gestation, breech delivery, malformations, and cases included after the trial was closed (23) . Furthermore, the standardized ITT analysis was extended to include not only validated umbilical cord blood samples, but all cord blood determinations performed, neonatal blood tests showing metabolic acidosis, and imputed data in cases with missing acid-base data. Table 2 also indicates that there were considerable variations in duration, enrollment pace and inclusion criteria among trials. The Plymouth, Swedish and Finnish RCTs ran for a period of 18 months or less with 94-135 enrollments/center/month, whereas the French and Dutch RCTs took 2 and 2½ years to complete, respectively, with an enrollment pace of 15-21 patients/center/ month. However, the Dutch RCT adjusted statistically for the stratified randomization by center (and parity). Less frequent use of the ST analysis methodology may have contributed to a slower gain in staff experience, so influencing clinical decisions and possibly affecting the study results. Differences in population sample size in relation to the total population were also considerable. These differences raise the concern, particularly in the French RCT, that the characteristics of the enrolled population contributed to outcomes that differed in degree and direction from those of the other RCTs.
Management protocols in labor
Fetal scalp blood sampling (FBS) for determination of pH was optional in all five RCTs but only the Plymouth and Dutch RCTs had guidelines for this ( Table 3 ). The interpretation algorithm was similar in all five RCTs (scalp blood pH ≥ 7.25, normal; 7.24-7.20, suspicious/pre-acidosis, repeat FBS; <7.20, abnormal/acidosis, deliver or reveal cause of hypoxia; in the Finnish RCT a pH <7.20 was an indication of immediate delivery). The Plymouth RCT used an earlier version of the STAN â monitor, the S8801 model, and a CTG+ST interpretation algorithm that differed from the other RCTs (Table 3 ). The T/QRS ratio and ST interval changes were read manually, where a T/ QRS ratio above a certain cut-off or a rapidly emerging change in the ST interval waveform was regarded as significant and warranted action (12, 24) . This situation may have reduced the reliability of the ST analysis when compared with the automated analysis used in the later RCTs.
Intrapartum interventions: FBS and operative delivery
The use of FBS ranged from 9.4 to 62% in the CTG-only groups (Table 4) . FBS was reduced in the CTG+ST arm in all RCTs, but the reduction was only significant in those with the highest use of FBS, i.e. the Finnish, French and Dutch RCTs. The total rates of ODFD were reduced in the CTG+ST arm in all RCTs except the Dutch study, but the reductions were only significant in the Plymouth and Swedish RCTs (Table 4) . Overall, the total operative delivery rate, including cesarean sections and instrumental vaginal deliveries, was significantly reduced only in the Swedish RCT.
Metabolic acidosis as an outcome parameter
Umbilical cord blood acid-base status at birth was an outcome parameter in all five RCTs (Table 5) . Paired cord blood samples from artery and vein were used, but validation of arterial blood samples was only performed in the Swedish (revised data report), French and Dutch RCTs. However, the validation criteria were not uniform (Table 3) . Base deficit (BD) was calculated in the extracellular fluid (BD ecf ) from measured values of pH and PCO 2 in all trials except the Finnish RCT, in which BD was calculated in blood (BD blood ). Hence, the incidence of metabolic acidosis in the Finnish RCT cannot be compared directly with that of the other RCTs, because, when calculated in blood, BD is considerably higher and metabolic acidosis subsequently more prevalent than when calculated in extracellular fluid (25, 26) . Metabolic acidosis was defined as an umbilical cord artery blood pH < 7.05 in combination with a BD ecf > 12.0 mmol/L in all but the Finnish RCT. Using the pH and PCO 2 values obtained from blood gas analyzers, BD ecf can be calculated post hoc with the algorithm (in SI units): BD ecf = À0.9149 9 (0.23 9 PCO 2 9 10
. This algorithm was originally derived from the work by Siggaard-Andersen (27, 28) . The Finnish RCT used a Chiron Diagnostics 348 blood gas analyzer to calculate BD blood . By recalculating the Finnish RCT data with the BD ecf algorithm, the originally reported metabolic acidosis rates of 1.7% (12/714) in the CTG+ST analysis group and 0.7% (5/722) in the CTG-only group declined to 0.8% (6/714) and 0.6% (4/722), respectively [K. Ojala, personal communication to Welin et al. (7)]. The distinction between BD calculated in blood and that calculated in extracellular fluid is important for the diagnosis of metabolic acidosis, since the incidence of BD > 12.0 mmol/L might differ by a factor of 4 when using different BD algorithms (26) . Hence, for a correct comparison of BD values and metabolic acidosis rates, the same BD algorithm must be used in comparative studies and MAs.
In the perinatal period, BD ecf should be used rather than BD blood for determining metabolic acidosis, because the fetus/newborn has a relative increase in the size of the extracellular fluid compartment compared with that of the intravascular compartment (29) (30) (31) . This makes BD ecf more stable and less susceptible to momentary perturbations. The impact of different BD calculations was demonstrated in the Dutch RCT (19) , showing a significant reduction in metabolic acidosis rate in the CTG+ST group with the BD blood algorithm [risk ratio (RR) 0.63, 95% CI 0.42-0.94] but not with the BD ecf algorithm (RR 0.70, 95% CI 0.38-1.28). With BD blood the metabolic acidosis rates were 1.6 and 2.6%, and with BD ecf they were 0.7 and 1.1%.
Neonatal outcome: metabolic acidosis, neonatal intensive care admissions
The proportion of missing cord blood gas data was available only in the Swedish (7.4%) and Finnish (2.4%) publications (Table 5 ), but the Dutch authors reported an estimated incidence of 20% missing values (16) . Imputed data were calculated in the Dutch RCT and in the revised version of the Swedish RCT. It can be inferred from the thesis of Westgate (24) that cases with missing cord blood gas data were excluded from the analyses of neonatal variables, and possibly also of other variables in the Plymouth RCT. Thirty-six cases (2.4%) with missing blood gas data were excluded from analyses of neonatal outcome variables in the Finnish RCT [comparative data retrieved from Becker et al. (1) ] and apparently cases with missing cord blood data were excluded from the ITT analyses in the French RCT.
Westgate et al. (12) presented the results of the Plymouth RCT as the OR of CTG alone vs. CTG+ST. For comparison with the other RCT results we recalculated these figures to RR of CTG+ST vs. CTG alone (Table 5) . Following RR calculation there was a 62% reduction in metabolic acidosis in the CTG+ST group, but the study was underpowered to demonstrate a significant difference in this outcome. Nonsignificant differences were also found for pH < 7.15, pH < 7.05, Apgar score <7 at 5 min, and admissions to the neonatal intensive care unit (NICU).
In a re-examination of the original data from the Swedish database (17) , neonates with single vessel cord blood acid-base values, those with missing cord blood data but with neonatal blood gases and/or lactate indicating an affected acid-base status during the first hour of life, and imputed data in the group with missing data were included in the ITT analysis of metabolic acidosis. The revised Swedish RCT is the only study that report standardized ITT analyses as it included all randomized cases, irrespective of eligibility and availability of cord blood gas data. The significant difference in rates of metabolic acidosis between the CTG+ST and CTG-only groups remained (the original figures of 0.69% vs. 1.49% were recalculated to 0.66% vs. 1.33%). The original RCT (13) showed an RR for metabolic acidosis of 0.47 with 95% CI 0.25-0.86 (p = 0.015). After correction for misclassified cases, the RR for metabolic acidosis was 0.48 with 95% CI 0.24-0.96 (p = 0.038) while the standardized ITT yielded an RR for metabolic acidosis of 0.50 with 95% CI 0.28-0.88 (p = 0.019) (17) .
As mentioned, the Finnish RCT used a different equation to calculate BD. After communication with the principal author, Welin et al. (7) reported the incidence of metabolic acidosis when the original BD blood was recalculated to BD ecf , showing a reduction from 12 to 6 among the 714 cases in the CTG+ST group and from 5 to 4 among the 722 cases in the CTG-alone group. Using the same BD ecf algorithm as in the other RCTs, the total number of cases with metabolic acidosis was reduced from 17 to 10. The RR (95% CI) for metabolic acidosis in the CTG+ST arm of 2.43 (0.86-6.85) was reduced to 1.52 (0.43-5.35) ( Table 5 ). This does not alter the original conclusion that there was no significant difference between the groups, but it reduces the differences between the results of the Finnish RCT and those from Plymouth, Sweden and the Netherlands. This recalculation also reduces the reported heterogeneity in the incidence of metabolic acidosis.
In the French RCT, Vayssi ere et al. (15) reported a total of seven cases of BD ecf > 12.0 mmol/L with validated blood samples in the CTG+ST group (7/399, 1.75%) but presented eight cases of metabolic acidosis (8/399, 2.0%), defined as pH < 7.05 and BD ecf > 12.0 mmol/L. This divergence remains unexplained. Moreover, the higher metabolic acidosis rate in the CTG+ST group compared with the CTG-alone group (2.0% vs. 1.25%) is (18, 19) . The number of cases with metabolic acidosis was corrected from 50 to 46, but the original RR of 0.70 (95% CI 0.38-1.28) remained unchanged in the CTG+ST arm (16, 19) . Admissions to the NICU were reported in all five RCTs (Table 5) . Reductions in NICU admissions by 9-23% in the CTG+ST groups were reported in four RCTs and an increase by 1% in one RCT; none of these differences were statistically significant. Neonatal encephalopathy and/or seizures were reported in all trials except in the Plymouth RCT; no significant differences were found except for encephalopathy stage 1-3, which was significantly less common in the CTG+ST group in the Swedish RCT. However, neonatal encephalopathy was not uniformly defined; only the Swedish and Dutch RCTs defined this outcome according to Sarnat & Sarnat criteria stage 1-3 (32) . The Swedish RCT reported on stage ≥1 and stage ≥2 separately, while the Dutch RCT reported only on stage ≥2. Westgate provided more details on neonatal outcome in the Plymouth RCT in her thesis (24) , but they do not allow for the retrospective classification of neonatal encephalopathy. The Finnish RCT reported more cases of neonatal seizures than cases with a diagnosis of encephalopathy, which could be in conflict with the Sarnat & Sarnat definition where seizure is defined as stage 2 encephalopathy. The French RCT did not report encephalopathy. Therefore, the impact of CTG+ST analysis on neonatal encephalopathy cannot be adequately determined for all cases included in the trials.
Perinatal mortality was reported in all RCTs except for the Plymouth study. Data retrieved from the thesis by Westgate (24) reveal two perinatal deaths in the CTG+ST group and none in the CTG-alone group. No RCT showed a significant difference in perinatal mortality between the study and control groups (Table 5) , but all studies were underpowered to evaluate this outcome.
Summary of major strengths and weaknesses

Plymouth trial
This initial RCT of the CTG+ST methodology introduced the essential criteria for intervention used in the subsequent trials. The trial used an older ST analysis methodology than the other trials, and supports the hypothesis that ST analysis reduces metabolic acidosis and operative delivery.
Strengths.
• Single-center RCT, suggesting lower risk of inconsis- • Underpowered to evaluate metabolic acidosis, recruitment goal not achieved 
Swedish trial
The original trial was criticized for the exclusion from the ITT analysis of randomized cases that did not fulfill the inclusion criteria. This was addressed in a revised and standardized ITT analysis, i.e. inclusion of all randomized cases irrespective of eligibility.
Strengths.
• Power calculation related to metabolic acidosis Weaknesses.
• No clear guidelines for FBS use • Errors in number of metabolic acidosis in original article
Finnish trial
This is a small trial, aimed to show differences in the incidence of severe fetal acidemia instead of metabolic acidosis. When metabolic acidosis was calculated, a different BD algorithm was used.
Strengths.
• Single-center RCT, suggesting lower risk of inconsistent management
• Short trial period, high recruitment pace Weaknesses.
• Primarily not aimed to show metabolic acidosis difference • Recruitment goal not achieved for primary outcome variable "cord artery pH < 7.10"
• Inclusion criterion, "amniotomy," provides no information on fetal risk 
French trial
The eligibility criteria of this trial allowed inclusion of cases with a CTG pattern that indicated fetal hypoxia before the CTG+ST monitoring was started, violating the ST analysis clinical guidelines and different from the other trials. It may be questioned if this trial should be pooled together with the other trials in comparisons.
Strength.
• Confirmed that ST analysis had no benefit in addition to conventional CTG in labors with pre-existing evidence of fetal compromise Weaknesses.
• Underpowered for evaluation of metabolic acidosis • Poor quality of umbilical cord blood samples, unreliable blood gas data
Dutch trial
The main weakness of the Dutch RCT is its low recruitment pace. This may have influenced the learning curve and the results of the trial, but the impact cannot be determined.
Strengths.
• Power calculation related to metabolic acidosis • Safety committee watch of serious adverse events • Well-defined inclusion criteria • Strict guidelines for FBS use related to CTG+ST pattern (but not to CTG pattern alone)
• Internal electronic monitoring in CTG-alone group • Largest RCT • Not completely standardized ITT but only 14 cases (0.25%) excluded from ITT
• Revised data article published with corrected and imputed cord blood gas data Weaknesses.
• Underpowered for metabolic acidosis, recruitment goal not achieved
• Long trial period, low recruitment pace, many centers involved • Errors in number of metabolic acidosis in original article
Conclusions
The perfect RCT to evaluate the CTG+ST methodology remains to be performed, though "perfect" is probably an unachievable goal. While the larger Plymouth, Swedish and Dutch RCTs point towards reduced metabolic acidosis rates and reduced operative interventions in the CTG+ST arm, the smaller Finnish and French RCTs point towards higher metabolic acidosis rates and minor differences in operative delivery rates. Because the Finnish RCT calculated BD in blood rather than in extracellular fluid, this led to a falsely elevated rate of metabolic acidosis in comparison with the other RCTs. An adjusted analysis points to a less divergent result. The French RCT uses an inclusion criterion -abnormal CTG -which is in conflict with the premise for the use of CTG+ST, as ST events may not appear de novo when fetal hypoxia is already present. Moreover, the quality of cord blood samples used in the study is low.
All RCTs, except for the Swedish one, were underpowered for the primary outcome of metabolic acidosis; only the Plymouth RCT was adequately powered for the primary outcome of ODFD. The inclusion criteria varied considerably among the trials, rendering any comparison of the primary outcomes problematic with such widely varying a priori risk factors. This finding alone could explain some of the differences.
Finally, the conduct of the RCTs, including recruitment pace and total enrollment, interim analysis, and accounting for ITT, reflect the difficulties inherent in the undertaking of large clinical trials. These variations contribute to the drawbacks of any subsequent MAs, as they will enhance heterogeneity effects. This is addressed further in a separate appraisal of the previously published MAs (33) .
